Table 1.
Population | Cohort | Status | n | Totals | Effective |
---|---|---|---|---|---|
EUR | PGC+deCODE | Case | 14,522 | 313,463 | 55,397 |
Control | 298,941 | ||||
MVP | Case | 22,260 | 445,847 | 84,594 | |
Control | 423,587 | ||||
iPSYCH2 | Case | 4,733 | 100,390 | 18,039 | |
Control | 95,657 | ||||
MGB | Case | 456 | 24,544 | 1,790 | |
Control | 24,088 | ||||
Yale–Penn 3 | Case | 310 | 1,781 | 1,024 | |
Control | 1,471 | ||||
Total | Case | 42,281 | 886,025 | 161,053 | |
Control | 843,744 | ||||
AFR | PGC | Case | 3,848 | 9,745 | 9,314 |
Control | 5,897 | ||||
MVP | Case | 14,946 | 112,526 | 51,843 | |
Control | 97,580 | ||||
Yale–Penn 3 | Case | 271 | 937 | 770 | |
Control | 666 | ||||
Total | Case | 19,065 | 123,208 | 64,460 | |
Control | 104,143 | ||||
AMR | MVP | Case | 2,774 | 38,289 | 10,292 |
Control | 35,515 | ||||
EAS | MVP | Case | 194 | 6,843 | 754 |
Control | 6,649 |
PGC is not a single cohort but comprises several individual cohorts, as described10